|
1
|
Jiang Y, Han QJ and Zhang J:
Hepatocellular carcinoma: Mechanisms of progression and
immunotherapy. World J Gastroenterol. 25:3151–3167. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Amarapurkar AD, Rege JD, Joshi AS, Vaiphei
K and Amarapurkar DN: Utilization of antihepatocyte clone OCH1E5
(Hep Par 1) in histological evaluation of liver tumors. Indian J
Pathol Microbiol. 49:341–344. 2006.PubMed/NCBI
|
|
3
|
Negrut N, Khan SA, Bungau S, Zaha DC, Aron
CR, Bratu O, Diaconu CC and Ionita-Radu F: Diagnostic challenges in
gastrointestinal infections. Rom J Mil Med. 123:83–90. 2020.
|
|
4
|
Draghici T, Negreanu L, Bratu OG, Stoian
AP, Socea B, Neagu TP, Stanescu AM, Manuc D and Diaconu CC:
Paraneoplastic syndromes in digestive tumors: A review. Rom
Biotechnol Lett. 24:813–819. 2019.
|
|
5
|
Quaglia A: Hepatocellular carcinoma: A
review of diagnostic challenges for the pathologist. J Hepatocell
Carcinoma. 5:99–108. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Lai YS, Cheng CC, Lee MT, Chao WT, Lai YC,
Hsu YH and Liu YH: The prognostic value of cytokeratin and sal-like
protein 4 expression in hepatocellular carcinoma and intra-hepatic
cholangiocarcinoma in Taiwan. Int J Med Sci. 15:1746–1756.
2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Ferrell LD: Hepatocellular carcinoma and
its variants. In: Odze and Goldblum Surgical Pathology of the GI
Tract, Liver, Biliary Tract, and Pancreas. 3rd edition. Elsevier
Saunders Publishing House, pp1549-1557, 2015.
|
|
8
|
Torbenson MS, Ng IOL, Park YN, Roncalli M
and Sakamoto M: Hepatocellular carcinoma, chapter 8: Tumours of
tumours of the liver and intrahepatic bile ducts. In: WHO
Classification of Tumours, Digestive System. 5th edition,
pp229-239, 2019.
|
|
9
|
Kutlesic C, Katic V, Veliekovic L and
Katic K: Atypical adenomatous hyperplasia in liver cirrhosis. Arch
Oncol. 12 (Suppl 1):S10–S11. 2004.
|
|
10
|
Shafizadeh N and Kakar S: Diagnosis of
well-differentiated hepatocellular lesions: role of
immunohistochemistry and other ancillary techniques. Adv Anat
Pathol. 18:438–445. 2011.
|
|
11
|
Epîngeac ME, Găman MA, Diaconu CC, Gad M
and Găman AM: The evaluation of oxidative stress in obesity. Rev
Chim (Bucharest). 70:2241–2244. 2019.
|
|
12
|
Dumitru N, Cocolos A, Caragheorgheopol A,
Dumitrache C, Bratu OG, Neagu TP, Diaconu CC and Ghemigian A:
Collagen-the ultrastructural element of the bone matrix. Rev Chim
(Bucharest). 69:1706–1709. 2018.
|
|
13
|
Van Eyken P, Sciot R, Paterson A, Callea
F, Kew MC and Desmet VJ: Cytokeratin expression in hepatocellular
carcinoma: An immunohistochemical study. Hum Pathol. 19:562–568.
1988.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Witjes CD, ten Kate FJ, Verhoef C, de Man
RA and Jzermans JN: Immunohistochemical characteristics of
hepatocellular carcinoma in non-cirrhotic livers. J Clin Pathol.
66:687–691. 2013.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Fan Z, van de Rijn M, Montgomery K and
Rouse RV: Hep Par 1 antibody stain for the differential diagnosis
of hepatocellular carcinoma: 676 tumors tested using tissue
microarrays and conventional tissue sections. Mod Pathol.
16:137–144. 2003.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Hanif R and Mansoor S: Hep par-1: A novel
immunohistochemical marker for differentiating hepatocellular
carcinoma from metastatic carcinoma. J Coll Physicians Surg Pak.
24:186–189. 2014.PubMed/NCBI
|
|
17
|
Kakar S, Gown AM, Goodman ZD and Ferrell
LD: Best practices in diagnostic immunohistochemistry:
Hepatocellular carcinoma versus metastatic neoplasms. Arch Pathol
Lab Med. 131:1648–1654. 2007.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Wang XY, Degos F, Dubois S, Tessiore S,
Allegretta M, Guttmann RD, Jothy S, Belghiti J, Bedossa P and
Paradis V: Glypican-3 expression in hepatocellular tumors:
Diagnostic value for preneoplastic lesions and hepatocellular
carcinomas. Hum Pathol. 37:1435–1441. 2006.PubMed/NCBI View Article : Google Scholar
|
|
19
|
DU JL, Wei LX and Wang YL: Expression and
clinicopathologic significance of GPC3 and other antibodies in
well-differentiated hepatocellular carcinoma. Zhonghua Bing Li Xue
Za Zhi. 40:11–16. 2011.PubMed/NCBI(In Chinese).
|
|
20
|
Coston WM, Loera S, Lau SK, Ishizawa S,
Jiang Z, Wu CL, Yen Y, Weiss LM and Chu PG: Distinction of
hepatocellular carcinoma from benign hepatic mimickers using
Glypican-3 and CD34 immunohistochemistry. Am J Surg Pathol.
32:433–444. 2008.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Suceveanu AI, Stoian AP, Mazilu L, Voinea
F, Hainarosie R, Diaconu CC, Pituru S, Nitipir C, Badiu DC, Ceausu
I and Suceveanu AP: Interferon-free therapy is not a trigger for
hepatocellular carcinoma in patients with chronic infection with
hepatitis C virus. Farmacia. 66:904–908. 2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Gheorghe G, Pantea Stoian A, Gaman MA,
Socea B, Neagu TP, Stanescu AMA, Bratu OG, Mischianu DLD, Suceveanu
AI and Diaconu CC: The benefits and risks of antioxidant treatment
in liver diseases. Rev Chim (Bucharest). 70:651–655. 2019.
|
|
23
|
Segatelli V, de Oliveira EC, Boin IF,
Ataide EC and Escanhoela CA: Evaluation and comparison of
microvessel density using the markers CD34 and CD105 in
regenerative nodules, dysplastic nodules and hepatocellular
carcinoma. Hepatol Int. 8:260–265. 2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Lau SK, Prakash S, Geller SA and Alsabeh
R: Comparative immunohistochemical profile of hepatocellular
carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma. Hum
Pathol. 33:1175–1181. 2002.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Du JL, Wang YL, Shi HY, Guo AT and Wei LX:
Expression of glypican-3, hepatocyte antigen, alpha-fetoprotein,
CD34 and CD10 in hepatocellular carcinoma: A clinicopathologic
analysis of 375 cases. Zhonghua Bing Li Xue Za Zhi. 41:309–13.
2012.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
26
|
Cui DJ, Wu Y and Wen DH: CD34, PCNA and
CK19 expressions in AFP-hepatocellular carcinoma. Eur Rev Med
Pharmacol Sci. 22:5200–5205. 2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Surcel M, Huică RI, Munteanu AN, Isvoranu
G, Pîrvu IR, Ciotaru D, Constantin C, Bratu O, Căruntu C, Neagu M
and Ursaciuc C: Phenotypic changes of lymphocyte populations in
psoriasiform dermatitis animal model. Exp Ther Med. 17:1030–1038.
2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Plotogea O, Ilie M, Sandru V, Chiotoroiu
A, Bratu O and Diaconu C: Cardiovascular and metabolic consequences
of liver transplantation: A review. Medicina (Kaunas).
55(E489)2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Nasir A, Lehrke HD, Mounajjed T, Said S,
Zhang L, Yasir S, Shah SS, Chandan VS, Smyrk TC, Moreira RK, et al:
Albumin in situ hybridization can be positive in adenocarcinomas
and other tumors from diverse sites. Am J Clin Pathol. 152:190–199.
2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Kakar S, Muir T, Murphy LM, Lloyd RV and
Burgart LJ: Immunoreactivity of Hep Par 1 in hepatic and
extrahepatic tumours and its correlation with albumin in situ
hybridization in hepatocellular carcinoma. Am J Clin Pathol.
119:361–366. 2003.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Shahid M, Mubeen A, Tse J, Kakar S,
Bateman AC, Borger D, Rivera MN, Ting DT and Deshpande V: Branched
chain in situ hybridization for albumin as a marker of
hepatocellular differentiation: Evaluation of manual and automated
in situ hybridization platforms. Am J Surg Pathol. 39:25–34.
2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Fang YW: Expression and significance of
hTERT, c-myc and Ki-67 in hepatocellular carcinoma. Xi Bao Yu Fen
Zi Mian Yi Xue Za Zhi. 25:338–340. 2009.PubMed/NCBI(In Chinese).
|
|
33
|
Zhou X, Zhu H and Lu J: PTEN and hTERT
gene expression and the correlation with human hepatocellular
carcinoma. Pathol Res Pract. 211:316–319. 2015.PubMed/NCBI View Article : Google Scholar
|
